Page 6,807«..1020..6,8066,8076,8086,809..6,8206,830..»

Dean’s Pharmacy turns 20

Posted: Published on June 6th, 2012

By Christina Verderosa In 1992, Dean Watts was a district pharmacy manager for Walmart in North Carolina when he decided, If I wanted to work that much, Id work for myself. Meanwhile, back in DeWitt, Larry Barnes, owner of Hampton Drug, decided it was time to sell his business. Both Barnes and Watts got what they wanted, and 20 years later, Deans Pharmacy is celebrating its anniversary. Deans Pharmacy in 1992 was a much different business than it is now. It was located on Court Square in part of the building that now houses Cox Realty, and was mostly a drug store, although it offered a few additional services such as UPS pickup and photo developing. But then Deans Pharmacy began to expand. Traffic slowed down [at the Court Square location], he said. I had the opportunity to buy the lot out here [on Whitehead Drive, across from DeWitt Hospital] and capture the traffic patterns that were changing. In June, 2000, the new Deans Pharmacy opened in its current location. Watts said the advantages were evident immediately. Were right across the street from the hospital and the doctors offices, he said, and we have plenty of parking. But Deans was … Continue reading

Posted in Pharmacy | Comments Off on Dean’s Pharmacy turns 20

Bio-Matrix' Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Posted: Published on June 6th, 2012

SAN DIEGO, CA--(Marketwire -06/06/12)- Bio-Matrix Scientific Group (BMSN) (BMSN) announced today that its Regen BioPharma unit has appointed three internationally renowned regenerative medicine experts to its Scientific Advisory Board (SAB). The new SAB members appointed are David White, M.D., PhD; Wei-Ping Min, M.D., PhD and Vlad Bogin, M.D. Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and PhD degrees from Cambridge University. Dr. Wei-Ping Min is Professor at the Lawson Health Research Center in Canada. He is inventor of siRNA therapeutics in the area of immunology and cell therapy to inhibit disease modalities. He is also the founder/cofounder of several biotech companies including MedVax Pharma Corp, and ToleroTech Inc. Dr. Min brings detailed scientific and mechanistic expertise to Regen BioPharma. He earned graduate and medical degrees from Nanchang University Medical School and the PhD degree from … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Bio-Matrix' Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Ontario, Canada’s McMaster University Researchers Discover Drug Destroys Human Cancer Stem Cells but Not Healthy Ones

Posted: Published on June 6th, 2012

HAMILTON, Ontario--(BUSINESS WIRE)-- A team of scientists at McMaster University in Ontario, Canada have discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments. "The unusual aspect of our finding is the way this human-ready drug actually kills cancer stem cells; by changing them into cells that are non-cancerous," said Mick Bhatia, the principal investigator for the study and scientific director of McMaster's Stem Cell and Cancer Research Institute (SCC-RI) in the Michael G. DeGroote School of Medicine. Unlike chemotherapy and radiation, thioridazine appears to have no effect on normal stem cells. The research, published in the science journal CELL, holds the promise of a new strategy and discovery pipeline for the development of anticancer drugs in the treatment of various cancers. The research team has identified another dozen drugs that have good potential for the same response. For 15 years, some researchers have believed stem cells are the source of many cancers. In 1997, Canadian researchers first identified cancer stem cells in certain types of leukemia. Cancer stem cells have since been identified in blood, breast, brain, lung, gastrointestinal, prostate and ovarian cancer. To test more than a … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Ontario, Canada’s McMaster University Researchers Discover Drug Destroys Human Cancer Stem Cells but Not Healthy Ones

AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

Posted: Published on June 6th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leading stem cell therapeutic and regenerative medicine company, AuxoCell Laboratories, Inc., today announced an agreement with CordVida, a Brazilian stem cell cryopreservation company, which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source cord tissue. With this agreement, AuxoCell broadens its international reach to South America. At AuxoCell, we are pleased by the opportunity to provide this groundbreaking technology to families around the globe, said Rouzbeh R. Taghizadeh, PhD, Chief Scientific Officer of AuxoCell Laboratories, Inc. CordVida is Brazils premier cord blood bank and adheres to the highest quality standards. It is for that reason that we have selected them as our exclusive partner in Brazil. Cord tissue has an abundant source of mesenchymal stem cells (MSCs). Currently, there is a significant amount of research underway focused on mesenchymal stem cells extracted from cord tissue. MSCs are rapidly becoming the leading stem cell in regenerative medicine studies, and MSCs from a variety of sources are in use in over 150 clinical trials. The AuxoCell cord tissue technology represents the gold standard in the industry, as its technology … Continue reading

Posted in Stem Cell Human Trials | Comments Off on AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

ChoiceCenter's Garrett Tanner: 1 Year after Stem Cell Treatments 2012 – Video

Posted: Published on June 6th, 2012

04-06-2012 21:49 In November 2007, gymnast Garrett Tanner had an accident while training that left him a quadriplegic. In 2010, he came to ChoiceCenter Leadership University (LV102) where he met fellow student Maynard Howe (LV100), Vice Chairman of Stemedica, a stem cell company. In May 2011, Garrett received his first stem cell treatment in Moscow. Stemedica donated the cells and ChoiceCenter students donated money for his rehabilitation therapy, transportation, food and housing. This video documents Garrett's progress as of May 2012. He will receive his second treatment later this summer. Read more: ChoiceCenter's Garrett Tanner: 1 Year after Stem Cell Treatments 2012 - Video … Continue reading

Comments Off on ChoiceCenter's Garrett Tanner: 1 Year after Stem Cell Treatments 2012 – Video

The real culprit behind hardened arteries? Stem cells, says landmark study

Posted: Published on June 6th, 2012

BERKELEY One of the top suspects behind killer vascular diseases is the victim of mistaken identity, according to researchers from the University of California, Berkeley, who used genetic tracing to help hunt down the real culprit. Zhenyu Tang (seated at microscope) examines vascular stem cells in culture along with Aijun Wang (left) and Song Li. The UC Berkeley researchers say that these newly discovered stem cells contribute to artery-hardening vascular diseases that can lead to heart attacks and strokes. (Photo courtesy of Song Li) The guilty party is not the smooth muscle cells within blood vessel walls, which for decades was thought to combine with cholesterol and fat that can clog arteries. Blocked vessels can eventually lead to heart attacks and strokes, which account for one in three deaths in the United States. Instead, a previously unknown type of stem cell a multipotent vascular stem cell is to blame, and it should now be the focus in the search for new treatments, the scientists report in a new study appearing June 6 in the journal Nature Communications. For the first time, we are showing evidence that vascular diseases are actually a kind of stem cell disease, said principal investigator Song … Continue reading

Comments Off on The real culprit behind hardened arteries? Stem cells, says landmark study

Stem cells are identified as real culprit behind heart attacks after case of mistaken identity that could …

Posted: Published on June 6th, 2012

Scientists previously thought heart attacks and strokes were caused by smooth muscle cells Stem cells multiply and caused arteries to harden Heart attacks affect 90,000 and strokes 150,000 in Britain every year By Emma Reynolds PUBLISHED: 11:17 EST, 6 June 2012 | UPDATED: 11:17 EST, 6 June 2012 The real culprit behind heart attacks and strokes is stem cells, researchers have claimed in a landmark study that could revolutionise treatment. Until now, scientists thought vascular health problems were triggered by smooth muscle cells. Now a team from the University of California in Berkeley have found a previously unknown stem cell, which causes the arteries to harden when it multiplies. Real hope: The cells can multiply and cause arteries to harden, blocking the blood's route to the heart or brain The groundbreaking work is set to completely change how heart attacks and strokes are treated, dramatically cutting the number of deaths, according the study published today in the journal Nature Communications. Heart attacks are the most common reason for people to need emergency treatment. Around 90,000 people in Britain have one each year - of whom around a third will die as a result. See the original post: Stem cells are … Continue reading

Comments Off on Stem cells are identified as real culprit behind heart attacks after case of mistaken identity that could …

Study reports seizure-freedom in 68 percent of juvenile myoclonic epilepsy patients

Posted: Published on June 6th, 2012

Public release date: 6-Jun-2012 [ | E-mail | Share ] Contact: Dawn Peters healthnews@wiley.com 781-388-8408 Wiley-Blackwell A 25-year follow-up study reveals that 68% of patients with juvenile myoclonic epilepsy (JME) became seizure-free, with nearly 30% no longer needing antiepileptic drug (AED) treatment. Findings published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), report that the occurrence of generalized tonic-clonic seizures preceded by bilateral myoclonic seizures, and AED polytherapy significantly predicted poor long-term seizure outcome. Patients with JME experience "jerking" of the arms, shoulders, and sometimes the legs. Previous evidence suggests that JME is a common type of epilepsy (in up to 11% of people with epilepsy), occurring more frequently in females than in males, and with onset typically in adolescence.. There is still much debate among experts over the long-term outcome of JME, and about which factors predict seizure outcome. To further investigate JME outcomes and predictive factors, Dr. Felix Schneider and colleagues from the Epilepsy Center at the University of Greifswald in Germany studied data from 12 male and 19 female patients with JME. All participants had a minimum of 25 years follow-up which included review of medical records, and telephone or in-person interviews. Sixty-eight … Continue reading

Comments Off on Study reports seizure-freedom in 68 percent of juvenile myoclonic epilepsy patients

The ATEC Autism Treatment Evaluation Checklist Now Available for Patients with Autism -.mp4 – Video

Posted: Published on June 6th, 2012

05-06-2012 00:53 WATCH THIS FOR THE AUTISM CHECKLIST.. Read the original post: The ATEC Autism Treatment Evaluation Checklist Now Available for Patients with Autism -.mp4 - Video … Continue reading

Comments Off on The ATEC Autism Treatment Evaluation Checklist Now Available for Patients with Autism -.mp4 – Video

Parkinson's Disease Vaccine Human Trial

Posted: Published on June 6th, 2012

Editor's Choice Main Category: Parkinson's Disease Also Included In: Immune System / Vaccines;Clinical Trials / Drug Trials Article Date: 05 Jun 2012 - 14:00 PDT Current ratings for: 'Parkinson's Disease Vaccine Human Trial' 4.2 (5 votes) The company hopes the vaccine may deliver a causative treatment for Parkinson's. Its development has been generously supported by the Michael J. Fox Foundation. The trial's primary endpoints are tolerability and safety of PD01A. According to AFFiRiS, the vaccine candidate, PD01A, represents "..the first agent worldwide aiming disease modification of Parkinson's rather than addressing symptomatic improvement only. PD01A targets a protein called alpha-Synuclein (alpha-syn) which plays a key role in the onset and progression of Parkinsons." PD01A is designed to teach the body's immune system to generate antibodies that target alpha-syn. The trial, involving 32 patients, will be carried out at the Confraternitt Privatklinik Josefstadt in Vienna, Austria. AFFiRiS CEO, Dr. Walter Schmidt, said: Even in its preliminary stages this new treatment concept was highly appreciated, as the renowned Michael J. Fox Foundation assented financial support to a total of 1,5 Mio. USD. Hence, this is one of the few projects outside of the USA considered worthy of support by the foundation." The company … Continue reading

Posted in Parkinson's Treatment | Comments Off on Parkinson's Disease Vaccine Human Trial

Page 6,807«..1020..6,8066,8076,8086,809..6,8206,830..»